In This Section


  • Gil Yosipovitch, MD, Appointed Chair of the Department of Dermatology at Temple

    Gil Yosipovitch, MD, has been appointed Professor and Chair of the Department of Dermatology at Temple University School of Medicine, effective September 1, 2013. Dr. Yosipovitch most recently served as Professor of Dermatology, Neurobiology and Anatomy, Comprehensive Cancer Center, Center for Integrative Medicine and Center for Bio-Molecular Imaging at the Wake Forest School of Medicine and Wake Forest Institute for Regenerative Medicine, in Winston-Salem, North Carolina.

  • Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Cente

    Richard I. Fisher, MD, a leading cancer center administrator and nationally recognized hematology/oncology expert who joined Temple Health on March 1, 2013, has been appointed President and CEO of Fox Chase Cancer Center. Fisher will also hold the title of Cancer Center Director of Fox Chase, serving as the principal investigator on the Cancer Center Support Grant (CCSG) from the National Cancer Institute. He will retain the title of Senior Associate Dean for Cancer Programs at Temple University School of Medicine.

  • Temple University School of Medicine Announces New Center for Metabolic Disease Research

    (Philadelphia, PA) – Temple University School of Medicine (TUSM) has launched a new Center for Metabolic Disease Research, which is committed to performing basic and clinical research identifying specific causes of metabolic diseases, and to discovering novel therapies for these diseases.

  • Temple University Hospital Ranked Among Region's Best Hospitals by U.S. News & World Report

    Temple University Hospital has once again been included among the region’s best hospitals in U.S. News & World Report's "Best Hospitals" rankings for 2013-14. U.S. News also recognized Temple for high performance in the following specialties: Cancer; Gastroenterology and GI Surgery; Gynecology; Nephrology; Neurology and Neurosurgery; Orthopaedics; Pulmonology; and Urology. Only about 15 percent of all hospitals are recognized for high performance as among the region’s best.

  • Temple University Hospital Earns American Heart Association's Get With The Guidelines®–Stroke Gold Plus Quality Achievement Award

    (Philadelphia, PA) – Temple University Hospital has earned the American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke Gold Plus Quality Achievement Award. The award recognizes Temple University Hospital’s commitment and success in implementing a higher standard of stroke care by ensuring that stroke patients receive treatment for at least 24 months according to nationally accepted standards and recommendations.

  • Two Temple University School of Medicine Faculty Members Selected for Prestigious NIH Posts

    (Philadelphia, PA) – Joseph Cheung, MD, PhD, Senior Associate Dean for Research and Professor of Medicine at Temple University School of Medicine, and Xiao-Feng Yang, MD, PhD, Professor of Pharmacology, Professor at the Cardiovascular Research Center and Professor at the Sol Sherry Thrombosis Research Center at Temple University School of Medicine, have been selected for prestigious posts as members of National Institutes of Health (NIH) study sections.

  • Temple Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents Related to Active Ingredient in Marijuana

    HIV, the virus that causes AIDS, is notorious for hiding within certain types of cells, where it reproduces at a slowed rate and eventually gives rise to chronic inflammation, despite drug therapy. But researchers at Temple University School of Medicine's Department of Pathology and Laboratory Medicine and Center for Substance Abuse Research (CSAR) recently discovered that synthetic anti-inflammatory substances distantly related to the active ingredient of marijuana may be able to take the punch out of HIV while inside one of its major hideouts – immune cells known as macrophages.

  • Clues to Heart Disease in Unexpected Places, Temple Researchers Discover

    A major factor in the advance of heart disease is the death of heart tissue, a process that a team of scientists at Temple University School of Medicine's (TUSM) Center for Translational Medicine think could be prevented with new medicines. Now, the researchers are one step closer to achieving that goal, thanks to their discovery of a key molecule in an unexpected place in heart cells – mitochondria, tiny energy factories that house the controls capable of setting off cells' self-destruct sequence.